Saifen Drugs (Hong Kong) Limited was established in Year 2011 with a vision to provide better healthcare at an affordable cost with innovative and niche products to the people of South East Asia.
From an API trading company based in Hong Kong, it quickly moved to sales, marketing and distribution of finished dose formulation business to realize it’s vision and diversified gradually to Vietnam, Myanmar, Philippines and Singapore markets.
Today it successfully operates in these countries through it’s affiliate companies. Saifen Drugs focusses on launch of first generics in the market in it’s quest to provide niche products at an affordable cost.
“Healthcare for all” is its motto and “Service before self” is it’s philosophy.
Saifen have specialized sales force in each country with dedicated team for marketing support
Saifen is having sound infrastructure and reach to each and every part of the country with multiple stock points
Saifen has it’s own dedicated regulatory team in each country of operation for on time product launch
Saifen is working on a unique “Direct to Customer” app, to deliver medicines to patient’s home/work place
Launch of first generic Palonosetron, Cefpirom, Cefoperazon+Sulbactam Cephalothin injection
Got seven special import quota for launching orphan drugs
Launch of first generic Carbidopa/Levodopa, Citicolin Injection, Morphine tablet
Launch of first generic Telmisartan+Amlodipine Melphalan, Busulphan, Erlotinib
A strong, dedicated regulatory team in each country ensures documentation is correct and registrations are fast tracked for early launch
A dedicated marketing and research analysis team ensures that we shortlist products with real potential and launch the first generics frequently in the market to keep an edge over competition
We provide correct market scenario with precise MOQ’s to ensure that business is having least variations after commercialization
Bringing NCE’s, conducting local Bio-equivalence studies, site transfer for newer products, first generic launches and focus on latest medical devices to bring NDDS makes us a partner of choice
To launch 30 new products in Yr. 2023
To launch five first generics in Yr. 2023
To file 200 product registrations by Yr. 2023
Hong Kong, Vietnam,
Myanmar, Philippines,
Portugal
